中年の血管リスク要因,パーキンソン病,パーキンソン病-認知症: ARIC研究

Mohini Johri¹, Valerie Morrill¹, Derrick N Okine²

¹National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD.

Neurology

|September 4, 2025

まとめ

中年期喫煙はパーキンソン病 (PD) とパーキンソン病認知症 (PDD) の発生率の低下と関連していました. 他の血管の危険因子はこの長期研究でPDまたはPDDの発達と関連を示さなかった.

科学分野:

神経学
流行病学について
公衆衛生

背景:

高血圧や糖尿病のような血管の危険因子 (VRF) は認知症に関連しています.
パーキンソン病 (PD) とパーキンソン病認知症 (PDD) のVRFの役割はあまり理解されていません.
以前の研究では喫煙がPDを予防する可能性があるが PDDに対する効果は不明である.

研究の目的:

中年期の血管疾患の危険因子とPDとPDDの発生リスクとの関連を調査する.
喫煙,高血圧,肥満,高コレステロール血症,糖尿病がPDとPDDの発生率に与える影響を分析する.

主な方法:

地域における動脈硬化リスク (ARIC) の前向きな縦断研究
45歳から64歳までの13,875人の成人を募集し,基値のVRFを評価した.
病歴,認知テスト,監視データを用いて 30年以上のPDと認知症の症例を判断した.

主要な成果:

中年の喫煙はPD (HR 0. 36) とPDD (HR 0. 41) の発生率の低下と有意に関連していました.
他の中年のVRF (高血圧,肥満,糖尿病,高コレステロール血症) とPDまたはPDDのリスクとの間に有意な関連性が見つかりませんでした.
この結果は,他のリスク要因や人口統計から独立していた.

結論:

中年の喫煙はパーキンソン病とパーキンソン病の認知症の減少率と関連しています
他の一般的な血管疾患の危険因子は,PDやPDDの発症リスクに影響を与えないようです.
VRFのライフコースの変化とこれらの関連性の基礎となるメカニズムを調査するには,さらなる研究が必要です.

さらに関連する動画

10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.3K

07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.0K

関連する概念動画

01:15

Parkinson's Disease: Overview

702

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

702

01:24

Parkinson's Disease: Treatment

375

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

375

01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

関連する実験動画